Cogent Biosciences Announces Annual Meeting of Stockholders
02. Juni 2022 08:00 ET
|
Cogent Biosciences, Inc.
CAMBRIDGE, Mass. and BOULDER, Colo., June 02, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Announces Presentation at European Hematology Association (EHA) Annual Congress
12. Mai 2022 10:00 ET
|
Cogent Biosciences, Inc.
CAMBRIDGE, Mass. and BOULDER, Colo., May 12, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results
10. Mai 2022 07:00 ET
|
Cogent Biosciences, Inc.
Initial bezuclastinib APEX data to be presented at the European Hematology Association (EHA) 2022 Annual Congress Building a portfolio of discovery stage programs, creating potential best-in-class...
Cogent Biosciences to Participate in the LifeSci Partners Immunology and Inflammation Symposium
06. Mai 2022 08:00 ET
|
Cogent Biosciences, Inc.
CAMBRIDGE, Mass. and BOULDER, Colo., May 06, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Presents Nonclinical Data at AACR Annual Meeting and Provides Updates on Portfolio Expansion at R&D Investor Event
11. April 2022 07:00 ET
|
Cogent Biosciences, Inc.
New bezuclastinib nonclinical data demonstrate superior selectivity against closely related kinases, as well as minimal brain penetration, compared with other KIT inhibitors ...
Cogent Biosciences to Host Virtual R&D Investor Event
29. März 2022 07:00 ET
|
Cogent Biosciences, Inc.
CAMBRIDGE, Mass. and BOULDER, Colo., March 29, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for...
Cogent Biosciences Provides Corporate Updates, Fourth Quarter and Full Year 2021 Financial Results
15. März 2022 07:00 ET
|
Cogent Biosciences, Inc.
APEX, SUMMIT and PEAK bezuclastinib clinical trials actively enrolling patients APEX initial clinical data presentation expected in the first half of 2022 R&D Investor Event planned for...
Cogent Biosciences Announces Upcoming Presentations at AACR Annual Meeting 2022
08. März 2022 17:10 ET
|
Cogent Biosciences, Inc.
CAMBRIDGE, Mass. and BOULDER, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences to Present at 11th Annual SVB Leerink Global Healthcare Conference
09. Februar 2022 07:00 ET
|
Cogent Biosciences, Inc.
CAMBRIDGE, Mass. and BOULDER, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Unum Therapeutics Reports First Quarter Financial Results and Provides Corporate Updates
11. Mai 2020 16:30 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced...